Abstract
This chapter proposes a general framework for the formal integration of model-based predictions and their uncertainty in the planning of prospective trials and in quantitative decision-making. Standard operating characteristics such as statistical power, which are conditional on a chosen effect size, quantify the performance of the design. Optimising trials based solely on power does not fully address the needs of drug development teams interested in understanding the performance of the compound as well as the performance of the proposed study design. Many Phase 3 trials fail due to lack of significant efficacy despite being adequately powered. Power does not take into consideration the likelihood of achieving the assumed treatment effect. Metrics such as probability of a correct decision, probability of a Go decision, and probability of reaching a target value are proposed to evaluate the performance of the compound and trial. A conceptual clinical trial simulation (CTS) approach is outlined for calculating these trial performance metrics and to evaluate the ‘false positive’ and ‘false negative’ error rates for the proposed metrics. An example is presented to illustrate the CTS procedure and show how different choices of trial design, analytic technique and trial metric influence the probability of making correct decisions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Azzalini A, Genz A (2009) mnormt: R package for multivariate normal and t distributions. http://cran.r-project.org/web/packages/mnormt/index.html. R Package version 1.3-3
Box GEP (1966) Use and abuse of regression. Technometrics 8:625–628
Chuang-Stein C, Kirby S, French J, Marshall S. Choose right metrics to enable sound decisions. Presented at the FDA/Industry workshop, Washington DC, 23 September 2009. (http://www.amstat.org/meetings/fdaworkshop/index.cfm?fuseaction=AbstractDetails&AbstractID=300608)
Kowalski KK, Olson S, Remmers AE, Hutmacher MM (2008) Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. Clin Pharm Ther 83:857–866
Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall S, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R (2007) Model-based drug development. Clin Pharm Ther 82:21–32
Sheiner LB (1997) Learning and confirming in clinical drug development. Clin Pharmacol Ther 61:275–291
Smith MK, Marshall S (2006) A Bayesian design and analysis for dose-response using informative prior information. J Biopharm Stat 16:695–709
Smith MK, Marshall A (2010) Importance of protocols for simulation studies in clinical drug development. Stat Methods Med Res (Available online. doi: 10.1177/0962280210378949; http://smm.sagepub.com/content/early/2010/08/03/0962280210378949)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Smith, M.K., French, J.L., Kowalski, K.G., Hutmacher, M.M., Ewy, W. (2011). Decision-Making in Drug Development: Application of a Model Based Framework for Assessing Trial Performance. In: Kimko, H., Peck, C. (eds) Clinical Trial Simulations. AAPS Advances in the Pharmaceutical Sciences Series, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7415-0_4
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7415-0_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7414-3
Online ISBN: 978-1-4419-7415-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)